BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  COVID-19 News: Ocugen Secures Manufacturing, Ampio Stops Study and More

  Please check out the biopharma industry’s COVID-19 stories that are trending for June 15, 2021.

  June 15, 2021

   · 

  3 min read

   · 

  BioSpace Editorial Staff
• 

  Business

  Mnemo Breaks French Series A Record, Targets Greater Tumor Specificity

  The Paris-based biotech will use the funds to create targeted immuno-oncology treatments for a broader range of patients with its next-generation CAR-T and epigenetics platform.

  June 15, 2021

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Business

  Cash is King for Up-and-Coming Biotechs: Four Financing Rounds Announced Today

  Umoja Biopharma, Alentis Therapeutics, RayzeBio and Camp4 Therapeutics are ramping up on series funds.

  June 15, 2021

   · 

  4 min read

   · 

  Kate Goodwin
• 

  Drug Development

  AstraZeneca Antibody Only 33% Better than Placebo at Preventing Post-Exposure COVID-19

  The failure marks a setback in the hunt for means other than vaccines to provide protection against the novel coronavirus and its variants.

  June 15, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Pivotal Late-Stage Trial Shows Major Depressive Drug Significantly Reduces Symptoms

  The study drug is a once-daily, two-week therapy developed by Sage Therapeutics and Biogen for major depressive disorder (MDD) and postpartum depression (PPD).

  June 15, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Drug Development

  Lilly Launches Head-to-Head Trial in Quest to Bolster Migraine Preventive Drug Emgality

  Eli Lilly and Company announced Tuesday the launch of a head-to-head study to compare once-monthly injectable Emgality® (galcanezumab-gnlm) with Nurtec® ODT (rimegepant) for the prevention of migraine.

  June 15, 2021

   · 

  2 min read

   · 

  Brandon May
• 

  Drug Development

  Revive Therapeutics Advances Repurposed Drug for Mild to Moderate COVID-19

  Repurposed drugs became the front-line defense against COVID-19 within a few months of the pandemic’s emergence. Now bucillamine, currently in Phase III trials in the U.S., may be poised to join them.

  June 15, 2021

   · 

  4 min read

   · 

  Gail Dutton
• 

  Drug Development

  After Controversial AD Drug Win, Biogen’s Retinal Gene Therapy Flops

  The company noted it would continue to assess the STAR study’s complete data set before confirming its future plans for clinical development of timrepigene emparvovec.

  June 15, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Genetown

  Current COVID-19 Vaccines Prove Efficacy Against Dangerous Delta Variant

  A recent study conducted by Public Health England found that the available vaccines were “highly effective” at preventing hospitalization after two doses.

  June 15, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  BioHarvest Sciences Inc. Reveals VINIA Anti-Aging Capabilities via Blood Flow Improvement

  VINIA(R)'s ability to increase dilation of arteries and to reduce blood vessel constriction allows it to fight the human aging process

  June 15, 2021

   · 

  6 min read